RBC Bioscience

RBC Bioscience Debt/EBITDA

The Total Debt to EBITDA Ratio of RBC Bioscience (6848.TWO) as of Oct 21, 2026 is 13.37. In the previous year, Total Debt to EBITDA Ratio was 32.44 — a change of -58.80% (lower).

Debt/EBITDA

13.37

YoY

-58.80%

Last updated:

Total Debt to EBITDA Ratio of RBC Bioscience is 2024 13.37 . Total Debt to EBITDA Ratio of RBC Bioscience was 2023 32.44 . It decreases by -58.80% lower compared to the previous year.

The RBC Bioscience Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
3.40 TWD
Jan 1, 2019
4.86 TWD
Jan 1, 2020
0.64 TWD
Jan 1, 2021
10.51 TWD
Jan 1, 2022
62.16 TWD
Jan 1, 2023
32.44 TWD
Jan 1, 2024
13.37 TWD
The RBC Bioscience Debt/EBITDA history
YEARDebt/EBITDAYoY
13.37-58.80%
32.44-47.81%
62.16+491.33%
10.51+1,543.78%
0.64-86.84%
4.86+42.81%
3.40—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Total Debt to EBITDA Ratio of RBC Bioscience is 13.37 in 2024.

Total Debt to EBITDA Ratio of RBC Bioscience changed from 32.44 to 13.37, representing a -58.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — RBC Bioscience

All Key Metrics — RBC Bioscience